*Retatrutide

Ah, another politician all of a sudden worried about glp-1’s and peptides. I think you’ve got bigger problems to worry about than weight-loss meds, Senator.

I wonder how much Big Pharma is paying him to go after glp-1’s and peptides 👀

Had a couple PepTracker App videos go viral on TikTok and the accounts just got banned for ‘community guidelines violations.’ But tons of other accounts straight-up shill peptides/glp-1’s and dish out awful medical advice with zero issues??? Make it make sense.

“My notes app filled with random ideas I had in the shower and a half-finished grocery list is totally the best place to track my peptide use” …is what nobody should be saying when we exist 💉🗒️

easily the best peptide/glp-1 tracking app

Impressive trial data! As with any protocol, accurate dosing and consistency can make all the difference. The GLP-1 space is only going to keep growing. Great time to be paying attention 🫡

> Peptides > Tracking them > Never missing a dose > Progress

New week starts tonight. Make sure your peptide schedule is on track and ready!

If your friends aren’t talking about: - Peptides - And how to track them Time to find new friends (and download us)

Lilly’s oral GLP-1 (orforglipron) outperformed oral semaglutide in A1C and weight loss in a head-to-head T2D trial published in The Lancet. This is meaningful comparative data. But let’s add some context… 👇

The biggest GLP-1 breakthrough won’t be a stronger molecule. It’ll be better adherence. Pills increase access. Systems increase outcomes.

RFK Jr. was just on Joe Rogan’s podcast and said ~14 peptides currently restricted under the FDA’s Category 2 list could soon be eligible for legal compounding again. If implemented, that would materially EXPAND peptide access in the U.S. Category 2 status currently restricts

Incoming peptide frenzy 👀

If this plays out, we’re entering a more regulated phase of the peptide market…but that doesn’t necessarily make it simpler. Gray markets don’t disappear overnight. They evolve. Access and enforcement often expand at the same time. That increases fragmentation. More

The peptide gray market will never go away. There’s already so many compounding pharmacies selling crazy marked up peptides they also bought from the gray market.

Peptide Sciences, arguably one of the largest research peptide vendors, just announced they’re shutting down. That’s a pretty big deal considering how long they’ve been around. It also likely won’t be the last. As compounding pharmacies gain clearer pathways to prescribe

Peptide Sciences shutting down isn’t the story. The story is the peptide market shifting underneath it. When access moves from research vendors to compounding pharmacies, the ecosystem changes. Some companies disappear. New ones replace them.

The FDA is expected to lift its ban on injectable peptides from compounding pharmacies. The regulatory tide is finally shifting.

Eli Lilly's orforglipron just got approved as the first GLP-1 pill for weight loss. A lot of people who passed on injections are about to reconsider. The barrier to entry just got a lot lower.